Navigation Links
TapImmune, Inc. to Webcast, Live, at VirtualInvestorConferences.com February 2
Date:1/30/2017

JACKSONVILLE, Fla., Jan. 30, 2017 /PRNewswire/ -- TapImmune, Inc (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today announced that Glynn Wilson, Chief Executive Officer and Dr John Bonfiglio, Chief Operating Officer, will present live at VirtualInvestorConferences.com on February 2, 2017.

DATE: Thursday, February 2, 2017
TIME: 12:15pm Eastern Time
LINK: http://tinyurl.com/201prepr

This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register and run the online system check to save time and receive event updates.

Learn more about the event at www.VirtualInvestorConferences.com.

TapImmune Corporate Highlights

  • Potential to be dominant player in T-cell cancer vaccines by eliciting both helper and killer T-cell responses
  • Evaluating lead candidate in four Phase 2 studies, some with FDA Fast Track and Orphan Disease Status
  • Highly vetted technology: Collaborations with Mayo Clinic, AstraZeneca, Memorial Sloan Kettering Cancer Center, U.S. Dept. of Defense
  • Compelling Phase 1 data show robust and enduring immune response against vaccine targets
  • Multiple upcoming clinical value inflection points

About TapImmune, Inc.

TapImmune Inc. is a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease. The Company's peptide or nucleic acid-based immunotherapeutics comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate patients' killer T-cells and helper T-cells, or to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities, including immune checkpoint inhibitors.

Please visit the Company's website at www.tapimmune.com for more details.

About VirtualInvestorConferences.com
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tapimmune-inc-to-webcast-live-at-virtualinvestorconferencescom-february-2-300398493.html


'/>"/>
SOURCE TapImmune, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. BioLight Israeli Life Sciences Investments Ltd. to Webcast, Live, at RetailInvestorConferences.com on September 12th
2. 22nd Century Group, Inc. CEO to Webcast, Live, at RetailInvestorConferences.com on December 5th
3. Organovo Holdings, Inc. to Webcast, Live, at RetailInvestorConferences.com September 11
4. NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7
5. CohBar, Inc. to Webcast, Live, at VirtualInvestorConferences.com October 1
6. Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast
7. Lightlake Therapeutics Inc. March 5th Presentation At VirtualInvestorConferences.com Now Available For On-Demand Viewing
8. Die Präsentation von Lightlake Therapeutics Inc. auf VirtualInvestorConferences.com vom 5. März steht jetzt auf Abruf zu Verfügung
9. ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7
10. Viveve to Webcast Live at VirtualInvestorConferences.com
11. DelMar Pharmaceuticals to Present an Interactive Live Webcast at VirtualInvestorConferences.com on October 1, 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... Biodex Medical ... and ambulation aid in one device. This assistive aid lifts patients safely from a ... harness and motorized lift mechanics. The Mobility Assist is the latest in a line ...
(Date:6/26/2017)... VIRGINIA (PRWEB) , ... June 26, 2017 , ... ... today that Melissa Kirkegaard, the former Associate Director of Product Development R&D at ... biological and pharmaceutical products at both start-up and established biopharma companies, has joined ...
(Date:6/23/2017)... ... June 23, 2017 , ... Biova, LLC., the leader in water ... Board of Directors. Dr. Henig will bring a wealth of scientific experience in the ... the Chief Technical and Scientific Officer of four major global companies in the last ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Academy of Model ... University Aviation Association (UAA), the unifying voice for collegiate aviation education, are launching ... teamwork, competition, and success through a STEM-based education platform. , Much like the ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):